We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




“Nanodaisies” Designed to Transport Drug Cocktail to Cancer Cells

By LabMedica International staff writers
Posted on 09 Jun 2014
The researchers are from the joint biomedical engineering program at North Carolina State University (Raleigh, USA) and the University of North Carolina at Chapel Hill (USA). More...
“We found that this technique was much better than conventional drug-delivery techniques at inhibiting the growth of lung cancer tumors in mice,” stated Dr. Zhen Gu, senior author of the study and an assistant professor in the joint biomedical engineering program. “And based on in vitro tests in nine different cell lines, the technique is also promising for use against leukemia, breast, prostate, liver, ovarian, and brain cancers.”

To construct the “nanodaisies,” the researchers started with a solution that contains a polymer called polyethylene glycol (PEG). The PEG forms long strands that have much shorter strands splitting off to either side. Researchers directly attach the anticancer drug camptothecin (CPT) onto the shorter strands and introduce the anticancer drug doxorubicin (Dox) into the solution.

PEG is hydrophilic; CPT and Dox are hydrophobic. As a result, the CPT and Dox cluster together in the solution, wrapping the PEG around themselves. This results in a daisy-shaped drug cocktail, only 50 nm in diameter, which can be injected into a cancer patient. Once injected, the nanodaisies glide through the bloodstream until they are absorbed by cancer cells. In fact, one of the reasons the researchers chose to use PEG is because it has chemical properties that prolong the life of the drugs in the bloodstream.

Once in a cancer cell, the drugs are released. “Both drugs attack the cell’s nucleus, but via different mechanisms,” said Dr. Wanyi Tai, lead author and a former postdoctoral researcher in Dr. Gu’s lab. “Combined, the drugs are more effective than either drug is by itself,” Dr. Gu concluded. “We are very optimistic about this technique and are hoping to begin preclinical testing in the near future.”

The study’s findings were published May 27, 2014, in the journal Biomaterials.

Related Links:

North Carolina State University
University of North Carolina at Chapel Hill



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.